Protecting Children’s Privacy at Home, at School, and Everywhere in Between
Summary
Young people today face surveillance unlike any previous generation, at home, at school, and everywhere in between. Constant use of technology while their brains are still developing makes them uniquely vulnerable to privacy harms, including identity theft, cyberbullying, physical risks, algorithmic labeling, and hyper-commercialism. A lack of privacy can ultimately lead children to self-censor and can limit their opportunities. Already-vulnerable populations—who have fewer resources, less digital literacy, or are non-native English speakers—are most at risk.
Congress and the Federal Trade Commission (FTC) have repeatedly considered efforts to better protect children’s privacy, but the next administration must ensure that this is a priority that is actually acted upon by supporting strong privacy laws and providing additional resources and authority to the FTC and support to the Department of Education (ED). The Biden-Harris administration should also establish a task force to explore how to best support and protect students. And the FTC should use its current authority to increase its understanding of the children’s technology market and robustly enforce a strong Children’s Online Privacy Protection Act (COPPA) rule.
AI is transforming how children learn and live, and policymakers, industry, and educators owe it to the next generation to set in place a responsible policy that embraces this new technology while at the same time ensuring all children’s well-being, privacy, and safety is respected.
A peer support option should be integrated into the 988 Suicide and Crisis Lifeline so that 988 service users can choose to connect with specialists based on a shared lived experience.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.